Hypothalamic obesity is a rare, treatment-resistant condition that occurs due to hypothalamic injury, leading to rapid weight gain, hyperphagia, low energy expenditure, and severe metabolic complications. According to Aditya Singh et al., 2025, obesity is one of the most pressing public health concerns, currently affecting one billion people globally. Therapies in development for hypothalamic obesity include GLP-1 receptor agonists, melanocortin receptor agonists, and amylin analogues, with growing interest in targeted neuroendocrine agents. According to the hypothalamic obesity drug pipeline analysis by Expert Market Research, increasing R&D initiatives and clinical trials are expected to drive strong growth in the coming years.
Major companies involved in the hypothalamic obesity pipeline analysis include Rhythm Pharmaceuticals, Inc., Amylin Pharmaceuticals, LLC, and others.
Leading drugs currently in the pipeline include LB54640, RM-718, and others.
Pipeline growth for hypothalamic obesity drugs is driven by increasing clinical trials, novel neuroendocrine-targeted therapies, and rising collaborations among biopharma companies to address unmet treatment needs.
The Hypothalamic Obesity Pipeline Analysis Report by Expert Market Research gives comprehensive insights into hypothalamic obesity therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for hypothalamic obesity. The hypothalamic obesity report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hypothalamic obesity pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hypothalamic obesity treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hypothalamic obesity.
Read more about this report - Request a Free Sample
Hypothalamic obesity is a rare condition caused by damage or structural abnormalities in the hypothalamus, often following brain tumors, surgery, trauma, or inflammation. Disruption of the melanocortin-4 receptor (MC4R) pathway reduces energy expenditure and increases hunger, leading to rapid and sustained weight gain, typically within six to twelve months after injury.
Hypothalamic obesity treatments focus on lifestyle management, pharmacotherapy, and emerging targeted therapies. Medications like setmelanotide help regulate appetite and energy expenditure, offering improved weight control and reduced hyperphagia in affected patients. In August 2025, Rhythm Pharmaceuticals advanced the hypothalamic obesity market pipeline with FDA acceptance of a supplemental New Drug Application (sNDA) for setmelanotide. Phase 3 TRANSCEND trial data demonstrated a significant (19.8%) placebo-adjusted reduction in body mass index, supporting regulatory review in the United States and Europe.
The global obesity burden is rapidly increasing. According to Aditya Singh et al., 2025, the disease currently affects one billion people, including 650 million adults, with 2.8 million annual deaths. Prevalence is 14% globally and projected to reach 24% by 2035, impacting nearly 2 billion individuals. In developing regions, particularly Asia, lifestyle changes and higher consumption of calorie-dense foods drive rising obesity rates, creating a growing demand for hypothalamic obesity therapeutics.
This section of the report covers the analysis of hypothalamic obesity drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The hypothalamic obesity pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 45%, covers a major share of the total hypothalamic obesity clinical trials. It is followed by phase III at 27%, and phase I at 9%. These advancements are poised to address the substantial unmet need for effective treatments in this area. The progression of these therapies through the pipeline offers hope for improved management of hypothalamic obesity, potentially enhancing patient outcomes and quality of life.
The drug molecule categories covered under the hypothalamic obesity pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The hypothalamic obesity report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hypothalamic obesity. Peptide-based therapies are gaining attention in the hypothalamic obesity drug pipeline to manage severe weight gain and uncontrolled hunger. For example, Setmelanotide, a melanocortin-4 receptor agonist, is under evaluation for its ability to regulate energy intake by targeting hypothalamic pathways. Early clinical studies have shown promising reductions in body mass index and hunger with minimal adverse effects.
The EMR report for the hypothalamic obesity pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hypothalamic obesity therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hypothalamic obesity clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hypothalamic obesity. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hypothalamic obesity drug candidates.
LB54640, an investigational oral melanocortin-4 receptor (MC4R) agonist, is being developed by Rhythm Pharmaceuticals. This Phase 2 study is assessing the efficacy and safety of LB54640 in patients aged 12 years and older with hypothalamic obesity. The study is examining the drug’s impact on weight reduction, hunger control, safety, and quality of life. Patients are receiving daily oral doses of LB54640 or placebo for 14 weeks, with an optional extension through Week 56 for continued evaluation.
RM-718, developed by Rhythm Pharmaceuticals, Inc., is an investigational weekly MC4R-specific agonist designed to target hypothalamic obesity (HO). This Phase 1 study is evaluating the safety, tolerability, and pharmacokinetics (PK) of RM-718 in healthy subjects with obesity and in patients with HO. The study is examining single and multiple ascending doses via weekly subcutaneous injections. RM-718 is highly selective, sparing MC1R, and aims to reduce body weight and hunger without causing hyperpigmentation.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hypothalamic Obesity Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for hypothalamic obesity. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hypothalamic obesity collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share